Clinical feasibility of a wearable, conformable sensor patch to monitor motor symptoms in Parkinson's disease

Autor: Katie Melton, Oliver Stumpp, Shyamal Patel, Babak Boroojerdi, John Wright, Jake Phillips, D. Tatla, Nikhil Mahadevan, Christian Otoul, Roozbeh Ghaffari, Nirav Sheth, Dolors Terricabras, Ellora Sen-Gupta, Kasper Claes, Briana Morey, Michael Markowitz

Publikováno v: Parkinsonism & Related Disorders. 61:70-76

Introduction Clinical assessment of motor symptoms in Parkinson's disease (PD) is subjective and may not reflect patient real-world experience. This two-part pilot study evaluated the accuracy of the NIMBLE wearable biosensor patch (containing an acc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc3aea47f9bf7e0589f81525687bb871
https://doi.org/10.1016/j.parkreldis.2018.11.024

Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors:1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study

Autor: Michael E. Weinblatt, R. van Vollenhoven, Oana Purcaru, Gerd-Rüdiger Burmester, D. Tatla, Irina Mountian, Clifton O. Bingham, C Arendt, Daniel E. Furst, Xavier Mariette, B. VanLunen, Vivian P. Bykerk, Paul Emery, D. van der Heijde

Publikováno v: Emery, P, Bingham, C O, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, van Vollenhoven, R, Arendt, C, Mountian, I, Purcaru, O, Tatla, D, VanLunen, B & Weinblatt, M E 2017, ' Certolizumab pegol in combination with dose-optimised methotrexate in DMARD-naïve patients with early, active rheumatoid arthritis with poor prognostic factors : 1-year results from C-EARLY, a randomised, double-blind, placebo-controlled phase III study ', Annals of the Rheumatic Diseases, vol. 76, no. 1, pp. 96-104 . https://doi.org/10.1136/annrheumdis-2015-209057
Annals of the Rheumatic Diseases, 76(1), 96-104. BMJ Publishing Group
Annals of the Rheumatic Diseases, 76(1), 96-104
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 76(1), 96-104. BMJ Publishing Group

ObjectivesTo assess the efficacy and safety of certolizumab pegol (CZP)+dose-optimised methotrexate (MTX) versus placebo (PBO)+dose-optimised MTX in inducing and sustaining clinical remission in DMARD-naïve patients with moderate-to-severe, active,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16beb40b48aecdf2daecc0a5293c6036
https://research.vumc.nl/en/publications/81c0ff53-1d6d-4c39-a333-acb94d49c292

Response to: ‘Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!’ by Boers

Autor: Michael E. Weinblatt, Xavier Mariette, Oana Purcaru, C Arendt, Paul Emery, D. Tatla, Daniel E. Furst, R. van Vollenhoven, D. van der Heijde, Gerd R Burmester, B. VanLunen, Vivian P. Bykerk, Irina Mountian, Clifton O. Bingham

Publikováno v: Emery, P, Bingham, C O, Burmester, G R, Bykerk, V P, Furst, D E, Mariette, X, van der Heijde, D, Vollenhoven, R V, Arendt, C, Mountian, I, Purcaru, O, Tatla, D, VanLunen, B & Weinblatt, M E 2016, ' Response to: 'Let's stop fooling ourselves. In RA, only ACR/EULAR criteria define remission and equate with absence of disease!' by Boers ', Annals of the Rheumatic Diseases, vol. 75, no. 10, pp. e69 . https://doi.org/10.1136/annrheumdis-2016-210083
Annals of the Rheumatic Diseases, 75(10), E69-E69
Annals of the Rheumatic Diseases, 75(10). BMJ Publishing Group

We would like to thank Dr Boers for his critical comments on our study raised in his eLetter,1 and address his concerns regarding our manuscript.2 First, we would like to emphasise that we are in support of the statements in the guidelines issued by

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::66d838b20a0a921873a97345240c08ee
https://doi.org/10.1136/annrheumdis-2016-210083

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.